lets think of it this way, anyone wanting to partner or buy out cytodyn is only interested in one thing - Leronlimab. they don't need the BOD any employees or real estate asset. the status of the development of Leronlimab does effect the leverage they have, sort of. FDA not giving approval is not as important if the other buyer knows this is near impossible for a small biotech and they are not a small biotech. You can assume this is the basis for a low amount of leverage, until a 3rd party shows up. then it is all about who gets it and not weather cytodyn can do it themselves.

you keep bringing up where cytodyn is now and there current status, however everyone at cytodyn HQ can easily go back to there day jobs. there is no despiration other than figuring out how to pay for future and current trials. Cytodyn has more than enough data to show they have something of great value.